ACC, AHA Issue Updated Chest Pain Data Standards

Chest pain is one of the leading reasons for adult emergency room visits in the United States, accounting for more than 7 million visits annually. Properly identifying and treating dangerous and life-threatening causes of chest pain is critical.

The 2021 American Heart Association/American College of Cardiology Guideline for the Evaluation and Diagnosis of Chest Pain underscored the need to reach a consensus for the definitions of chest pain. In an update to the 2021 guideline, this 2022 document standardizes related data elements for consistent reporting on chest pain cases and establishes a new definition set focusing on serious cardiovascular causes of chest pain and acute myocardial infarction.

Included in the document, data elements are grouped into three broad categories: chest pain, myocardial injury and myocardial infarction. Chest pain symptoms have traditionally been labeled “typical” or “atypical,” however, to define their expansive nature, the document divides chest pain syndromes into three categories: “cardiac,” “possible cardiac” and “noncardiac” based on the 2021 chest pain guideline. In addition, the writing committee writes that uniform definitions for myocardial infarction are needed to ensure accurate reporting of cardiac events across all clinical trials and registries. Data elements for procedure-related myocardial injury and procedure-related myocardial infarction are included in the document. The standardized definitions and data elements should be broadly applicable across patient care settings, electronic health records, quality and performance improvement initiatives, registries and public reporting programs.

The 2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction will publish online in the Journal of the American College of Cardiology and Circulation: Cardiovascular Quality and Outcomes on Tuesday, August 30, 2022 at 2:00 p.m. ET. It was developed in collaboration with the American College of Emergency Physicians and the Society for Cardiac Angiography and Interventions, and endorsed by the Society for Academic Emergency Medicine.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.